PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

PAM50 intrinsic breast cancer subtypes are prognostic independent of standard clinicopathologic factors. CALGB 9741 demonstrated improved recurrence-free (RFS) and overall survival (OS) with 2-weekly dose-dense (DD) versus 3-weekly therapy. A significant interaction between intrinsic subtypes and DD...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Minetta C, Pitcher, Brandelyn N, Mardis, Elaine R, Davies, Sherri R, Friedman, Paula N, Snider, Jacqueline E, Vickery, Tammi L, Reed, Jerry P, DeSchryver, Katherine, Singh, Baljit, Gradishar, William J, Perez, Edith A, Martino, Silvana, Citron, Marc L, Norton, Larry, Winer, Eric P, Hudis, Clifford A, Carey, Lisa A, Bernard, Philip S, Nielsen, Torsten O, Perou, Charles M, Ellis, Matthew J, Barry, William T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501351/
https://www.ncbi.nlm.nih.gov/pubmed/28691057
http://dx.doi.org/10.1038/npjbcancer.2015.23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501351/
https://www.ncbi.nlm.nih.gov/pubmed/28691057
http://dx.doi.org/10.1038/npjbcancer.2015.23

Ejemplares similares